The focus of Dr. Facciabene’s laboratory is on immunotherapy and the investigation of tumor immune response network. The work combines efforts in both basic research and clinical investigation to advance the understanding of tumor immunology and implement these new knowledges in the development of new and more efficacious therapies. His basic research includes the implementation of a new vaccination strategy utilizing mitochondria isolated from tumors or a new tumor vasculature antigen and the regulation of the immune surveillance and the tumor microenvironment by the gut microbiome. His clinic research includes the clinical development of new preclinical immunotherapies.
BS (Pharmaceutical Biotechnology Science (summa cum laude))
University of Bologna, Italy (Thesis: Centre of Drug Discovery, L'Aquila, Italy) Summa Cum Laude, 2000.
PhD (Cancer Rsrch & Molecular Biol & Biotechnology)
Univ of Perugia in collaboration with the Univ of California San Diego, San Diego, CA (coursework 11/01-5/05 in Italy; exam in CA 2/06), 2006.
Dr. Stavros Rafail (email@example.com) studied biology at the University of Bath, UK followed by a Master’s degree in Assisted Reproduction Technology at the University of Nottingham, UK and Master of Business Administration at the University of Liverpool. He received his PhD from the medical school of the Democritus University of Thrace in Greece studying the interplay of coagulation, inflammation and the complement system. Dr. Rafail joined the Ovarian Cancer Research Center on 2012, first as a postdoctoral fellow and then as a Research Associate under the supervision of Dr. Facciabene.
His current research interests include the development of tumor either alone or combined with existing therapies. Furthermore, he is also examining the interplay between the intestinal microbiota and the immune system, focusing on ways to improve existing and novel anti-cancer therapies.
Dr. Mireia Uribe-Herranz (firstname.lastname@example.org) holds a bachelor’s degree in Biotechnology from the Autonomous University of Barcelona. She obtained her Master’s degree in Immunology and received her PhD from the Physiology School at the University of Barcelona, studying the molecular bases of xenogeneic rejection to develop strategies to prolong graft survival.
Dr. Uribe-Herranz joined the Ovarian Cancer Research Center on 2013, as a postdoctoral fellow under the supervision of Dr. Facciabene. Her research interests include tumor immunology and the development of tumor immunotherapies. She is also focusing on ways to improve existing and novel anti-cancer therapies by studying the interaction between the intestinal microbiota and the immune system.
Dr. Stefano Pierini (email@example.com) gained his bachelor degree in Biotechnology followed by a Master’s degree in Biomolecular and Biofunctional Sciences at the University of Camerino, Italy. In 2013, Dr. Pierini joined the Ovarian Cancer Research Center as visiting doctoral student, he focused on the development of a Dendritic Cell based cancer vaccine which exploits aberrant tumor mitochondria as a source of antigens to drive anti-tumor immunity.
His current research interests range from the identification and validation of novel targets for cancer immunotherapy, to the development of therapeutic strategies such as cancer vaccines and adoptive T cell therapy of tumor-reactive T cells isolated from Tumor Infiltrating Lymphocytes (TILs) of patients or mice after administration of vaccine.